Detailed Narrative
Q4 & FY25 Financial Performance Highlights
Mankind Pharma reported a strong Q4 FY25 with revenue increasing 27% year-on-year to INR3,079 crores. For the full fiscal year 2025, revenue grew 19% to INR12,207 crores. The adjusted EBITDA margin for FY25 stood at 25.9%, surpassing the guidance of 25-26%, primarily driven by a 260 basis points expansion in gross margins to 71.4%. However, Q4 FY25 PAT decreased 10% to INR429 crores, impacted by higher finance costs and increased depreciation due to BSV consolidation.
BSV Acquisition and Integration Progress
The recent acquisition of BSV has significantly enhanced Mankind's presence in super specialty segments, particularly in gynaecology where it now holds a 10.4% market share. The integration process involved strategic initiatives, including the consolidation of BSV's prescription business into Mankind's platform. Management expects synergies of INR50-100 crores to materialize within 12-24 months from the acquisition date. Integration costs of INR25 crores were incurred in Q4 FY25, and amortization related to BSV assets increased depreciation by INR110 crores in Q4 FY25 and INR194 crores in FY25.
Domestic and International Business Growth
The domestic business grew 18% year-on-year in Q4 FY25, primarily driven by chronic outperformance and BSV contribution. For FY25, domestic revenue crossed INR10,000 crores, reaching INR10,675 crores with 9% organic growth. The chronic share (excluding BSV) increased to 39.2% in Q4 FY25 from 37.5% in Q4 FY24, outperforming IPM chronic growth by 1.3x. International business revenue doubled in Q4 FY25 to INR535 crores and grew 88% in FY25 to INR1,532 crores, with 37% organic growth for the full year.
Consumer Healthcare and Chronic Segment Focus
The consumer healthcare segment demonstrated strong growth, with revenue increasing 14% in Q4 FY25 to INR178 crores and 15% in FY25 to INR809 crores. This growth was supported by a 77% year-on-year growth in modern trade and e-commerce channels. Mankind continues to focus on its core five therapeutic areas: cardiac, anti-diabetes, gastro, gynae, and anti-infectives, with chronic therapy growth at 11% in Q4 FY25, outperforming IPM chronic growth of 8.7%.
R&D and Pipeline Updates
Mankind Pharma is making notable strides in R&D, with its new NCE molecule GPR119, targeting obesity, diabetes, and metabolic disorders, advancing to Phase II clinical trials. R&D expenses for Q4 FY25 were 2.8% of sales, and 2.2% for the full year. The company anticipates increasing R&D investment to 2.5-3% of revenue in FY26. Strategic partnerships for GLP-1 are being explored to launch products post patent expiry, anticipated next year.
Capital Allocation and Debt Management
The company reduced its net debt to INR5,784 crores as of March 31, 2025, resulting in an improved net debt to adjusted EBITDA ratio of 1.8x for FY25. This was aided by the monetization of a non-core asset for INR562 crores and repayment of INR3,000 crores worth of commercial papers. Mankind targets an EBITDA to debt ratio of 1.1x-1.2x by FY26 and aims to retire all acquisition-related debt by FY28. Capex for FY25 was INR531 crores, representing 4.3% of revenue, in line with the 4-5% guidance for FY26.
Strategic Initiatives and Outlook
Mankind has undertaken significant internal reforms and strategic initiatives over the past year, including optimizing its workforce and digitizing operations, to build a strong foundation for future growth. The company expects its domestic revenue growth to outperform IPM by 1.2x in FY26 and projects EBITDA margins to be in the range of 25-26%. Management is confident that these strategic shifts will lead to sustained long-term growth and aims for a 30% EBITDA margin by fiscal 2030.